Related Experiment Video

Updated: Aug 24, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure

Hamang Patel1, John R Dietz, Ashley Owen

  • 1U.S.F. Cardiac Hormone Center, Department of Medicine, University of South Florida Health Sciences Center, and Medicine and Pharmacy Services, James A. Haley Veterans Medical Center, Tampa, Florida 33612, USA.

Experimental Biology and Medicine (Maywood, N.J.)
|June 1, 2004
PubMed

Insights

Vessel dilator and kaliuretic hormone increase urine flow and sodium excretion in congestive heart failure (CHF) patients. However, their combined administration does not produce additive diuretic or natriuretic effects beyond individual administration in severe CHF.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Congestive heart failure (CHF) is associated with impaired cardiovascular peptide hormone function.
  • Vessel dilator and kaliuretic hormone show preserved effects in CHF, unlike other natriuretic peptides.
  • Investigating combined administration of these hormones in severe CHF is warranted.

Purpose of the Study:

  • To determine if simultaneous administration of vessel dilator and kaliuretic hormone offers additive diuretic and natriuretic benefits in Class III CHF patients.
  • To compare the combined effects with individual hormone effects and control subjects.

Main Methods:

  • Infusion of vessel dilator and kaliuretic hormone at 100 ng/kg/min in Class III CHF patients.
  • Measurement of urine flow rate and sodium excretion rate.
  • Comparison with baseline and control CHF subjects.

Main Results:

  • Combined infusion increased urine flow rate 3.5-fold compared to baseline (P < 0.05).
  • Combined infusion enhanced sodium excretion rate up to 3.6-fold.
  • Diuretic and natriuretic effects were not additive compared to individual hormone administration.

Conclusions:

  • Vessel dilator and kaliuretic hormone exhibit diuretic and natriuretic properties in combination for Class III CHF.
  • The combined administration does not yield additive benefits over individual administration in this patient group.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...